FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2132854807> ?p ?o ?g. }

• W2132854807 endingPage "19" @default.
• W2132854807 startingPage "11" @default.
• W2132854807 abstract "Abstract Learning Objectives After completing this course, the reader will be able to:Recognize the reversible and irreversible toxicities associated with the management of newly diagnosed ovarian cancer.Better manage recurrent ovarian cancer.Identify the range of chemotherapeutic options in managing recurrent ovarian cancer. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists to plan for the long-term therapy of patients. However, many of the currently available front-line and salvage agents used in advanced ovarian cancer are associated with cumulative and/or irreversible toxicities that pose challenges in long-term planning. The irreversible effects associated with some of these therapies may render patients less tolerant to subsequent treatments and lead to a cycle of diminishing treatment options with each remission and disease relapse. Additionally, the potential for patients to experience cumulative toxicity must be carefully weighed against the goals of prolonging the disease-free interval and improving patient quality of life. A number of agents are available in the treatment armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, and topotecan), many, but not all of which are associated with cumulative toxicity. For instance, cumulative neurotoxicity associated with cisplatin as first-line therapy may diminish the option for retreatment with platinum at first relapse. In contrast, the main toxicity associated with topotecan is noncumulative, manageable myelosuppression. In this review, the major toxicities associated with the predominant chemotherapy agents used in advanced ovarian cancer are discussed along with selected management approaches in the context of long-term treatment planning and sequencing." @default.
• W2132854807 created "2016-06-24" @default.
• W2132854807 creator A5038170197 @default.
• W2132854807 date "2002-10-01" @default.
• W2132854807 modified "2023-09-24" @default.
• W2132854807 title "Management of Treatment-Related Toxicity in Advanced Ovarian Cancer" @default.
• W2132854807 cites W1522554466 @default.
• W2132854807 cites W1543697093 @default.
• W2132854807 cites W1608737321 @default.
• W2132854807 cites W1752100969 @default.
• W2132854807 cites W1835347798 @default.
• W2132854807 cites W1839380746 @default.
• W2132854807 cites W1845622004 @default.
• W2132854807 cites W1858072261 @default.
• W2132854807 cites W1863225814 @default.
• W2132854807 cites W1882099583 @default.
• W2132854807 cites W1910585037 @default.
• W2132854807 cites W1913802169 @default.
• W2132854807 cites W1930683464 @default.
• W2132854807 cites W1944650458 @default.
• W2132854807 cites W1950704147 @default.
• W2132854807 cites W1960327677 @default.
• W2132854807 cites W1979355909 @default.
• W2132854807 cites W1981343121 @default.
• W2132854807 cites W1983051867 @default.
• W2132854807 cites W1984390812 @default.
• W2132854807 cites W1993150719 @default.
• W2132854807 cites W2003476023 @default.
• W2132854807 cites W2006611167 @default.
• W2132854807 cites W2013403355 @default.
• W2132854807 cites W2019510314 @default.
• W2132854807 cites W2020670695 @default.
• W2132854807 cites W2025210272 @default.
• W2132854807 cites W2036846599 @default.
• W2132854807 cites W2039898149 @default.
• W2132854807 cites W2040863616 @default.
• W2132854807 cites W2042208317 @default.
• W2132854807 cites W2042608146 @default.
• W2132854807 cites W2044358936 @default.
• W2132854807 cites W2051557049 @default.
• W2132854807 cites W2066350187 @default.
• W2132854807 cites W2070825008 @default.
• W2132854807 cites W2085944495 @default.
• W2132854807 cites W2088865525 @default.
• W2132854807 cites W2092258095 @default.
• W2132854807 cites W2097777938 @default.
• W2132854807 cites W2098648310 @default.
• W2132854807 cites W2099650890 @default.
• W2132854807 cites W2116604772 @default.
• W2132854807 cites W2119148287 @default.
• W2132854807 cites W2124273755 @default.
• W2132854807 cites W2132093908 @default.
• W2132854807 cites W2134680286 @default.
• W2132854807 cites W2139109323 @default.
• W2132854807 cites W2147869809 @default.
• W2132854807 cites W2150870943 @default.
• W2132854807 cites W2152246203 @default.
• W2132854807 cites W2157610459 @default.
• W2132854807 cites W2257461724 @default.
• W2132854807 cites W2280816332 @default.
• W2132854807 cites W2290371619 @default.
• W2132854807 cites W2316280982 @default.
• W2132854807 cites W2403345865 @default.
• W2132854807 cites W2420977865 @default.
• W2132854807 cites W2438027381 @default.
• W2132854807 cites W2461434215 @default.
• W2132854807 cites W2466575804 @default.
• W2132854807 cites W2797611163 @default.
• W2132854807 cites W2994319618 @default.
• W2132854807 cites W3035130918 @default.
• W2132854807 cites W38682668 @default.
• W2132854807 cites W7268927 @default.
• W2132854807 doi "https://doi.org/10.1634/theoncologist.7-suppl_5-11" @default.
• W2132854807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12324629" @default.
• W2132854807 hasPublicationYear "2002" @default.
• W2132854807 type Work @default.
• W2132854807 sameAs 2132854807 @default.
• W2132854807 citedByCount "65" @default.
• W2132854807 countsByYear W21328548072012 @default.
• W2132854807 countsByYear W21328548072013 @default.
• W2132854807 countsByYear W21328548072014 @default.
• W2132854807 countsByYear W21328548072015 @default.
• W2132854807 countsByYear W21328548072016 @default.
• W2132854807 countsByYear W21328548072017 @default.
• W2132854807 countsByYear W21328548072018 @default.
• W2132854807 countsByYear W21328548072019 @default.
• W2132854807 countsByYear W21328548072020 @default.
• W2132854807 countsByYear W21328548072021 @default.
• W2132854807 countsByYear W21328548072022 @default.
• W2132854807 countsByYear W21328548072023 @default.
• W2132854807 crossrefType "journal-article" @default.
• W2132854807 hasAuthorship W2132854807A5038170197 @default.
• W2132854807 hasBestOaLocation W21328548071 @default.
• W2132854807 hasConcept C121608353 @default.
• W2132854807 hasConcept C126322002 @default.
• W2132854807 hasConcept C143998085 @default.
• W2132854807 hasConcept C151032500 @default.
• W2132854807 hasConcept C2776694085 @default.

• next